OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan ... - EON: Enhanced Online News (press release)
OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan .
OptiNose OKed for Phase III trial of nasal delivery tech - In-PharmaTechnologist.com
In-PharmaTechnologist.
OptiNose to begin Phase III trials with intranasal technology - Pharmaceutical Business Review
OptiNose to begin Phase III trials with intranasal technologyPharmaceutical Business ReviewOptiNose, a drug delivery company, has filed an investigational new drug (IND) with the FDA to use sumatriptan delivered with its novel drug delivery technology, in December 2011.
NuPathe Announces Allowance of Additional U.S. Patent Application for Its ... - MarketWatch (press release)
NuPathe Announces Allowance of Additional U.
OptiNose testing nose-to-brain delivery tech with migraine drug - FierceDrugDelivery
OptiNose testing nose-to-brain delivery tech with migraine drugFierceDrugDeliveryOptiNose is launching a Phase III trial to test the migraine drug sumatriptan with its intranasal nose-to-brain drug delivery technology.